Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1675
    +0.0018 (+0.16%)
     

  • GBP/USD

    1.2488
    -0.0023 (-0.18%)
     

  • Bitcoin GBP

    50,997.32
    -600.46 (-1.16%)
     

  • CMC Crypto 200

    1,325.25
    -71.29 (-5.10%)
     

  • S&P 500

    5,110.54
    +62.12 (+1.23%)
     

  • DOW

    38,301.37
    +215.57 (+0.57%)
     

  • CRUDE OIL

    83.93
    +0.36 (+0.43%)
     

  • GOLD FUTURES

    2,345.90
    +3.40 (+0.15%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

U.S. FDA panel to vote whether diabetes drug cuts cardiac death

Reuters - UK Focus

June 24 (Reuters) - An advisory panel to the U.S (Other OTC: UBGXF - news) . Food and Drug Administration will be asked to vote next week on whether a diabetes drug made by Eli Lilly & Co (Hanover: LLY.HA - news) and Boehringer Ingelheim cuts the risk of cardiovascular death, according to documents posted on the agency's website on Friday.

The review, posted on the agency's website, comes ahead of a June 28 meeting of outside advisors who will discuss the drug and recommend whether the label should include a claim that it cut the risk of heart problems in patients at high risk.

The FDA is not obliged to follow the advice of its advisory panels but typically does so. (Reporting by Toni Clarke in Washington)